Physician profile
Paul B Keiser
NPI 1457476699
$7,091.63
in general payments reported to CMS, 2019-2025
31 companies · $904 in 2025
The $904 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2020: $472 · 2021: $1,266 · 2022: $1,750 · 2023: $1,292 · 2024: $1,248 · 2025: $904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,433 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,432.75 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,883.32 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,000.07 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Regeneron Healthcare Solutions, INC. | $582.96 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $465.88 | 2020-2025 | |
| Genzyme Corporation | $450.74 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $407.38 | 2021-2025 | Cuvitru, Takhzyro |
| Aimmune Therapeutics, INC. | $249.45 | 2020-2022 | |
| Pfizer INC. | $243.57 | 2020-2025 | |
| Optinose US, INC. | $182.75 | 2021-2023 | |
| Kaleo, INC. | $169.15 | 2020-2024 | Auvi-Q |
| Grifols USA, LLC | $169.01 | 2021-2024 | Xembify, Prolastin-C Liquid |
| Genentech USA, INC. | $161.01 | 2021-2025 | Xolair |
| Abbvie INC. | $148.34 | 2022 | |
| Alk-Abello, INC | $134.50 | 2020-2022 | |
| Blueprint Medicines Corporation | $123.91 | 2023-2024 | Ayvakit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $95.30 | 2025 | Nemluvio |
| Amgen INC. | $92.93 | 2021-2024 | Tezspire |
| Incyte Corporation | $83.98 | 2022 | |
| Csl Behring | $81.25 | 2023-2025 | Hizentra |
| Biocryst US Sales Co., LLC | $72.58 | 2021-2025 | Orladeyo |
| Ars Pharmaceuticals Operations, INC. | $44.66 | 2025 | Neffy |
| Teva Pharmaceuticals USA, INC. | $36.00 | 2021 | |
| Tersera Therapeutics LLC | $32.92 | 2023-2024 | Quzyttir |
| Octapharma USA, INC. | $30.15 | 2020 | |
| Aerin Medical INC. | $27.47 | 2025 | |
| Alnylam Pharmaceuticals INC. | $26.93 | 2025 | Givlaari |
| Lilly USA, LLC | $26.73 | 2024 | Taltz, Ebglyss |
| Horizon Therapeutics Plc | $19.80 | 2023 | Actimmune |
| Uswm, LLC | $17.00 | 2021 | |
| Alexion Pharmaceuticals, INC. | $16.68 | 2023 | Strensiq |
| Hikma Pharmaceuticals USA | $15.21 | 2024 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Keiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.